ABSTRACT: Previous data from our group indicate that BMD is linked to chromosome 3p14-p21. Because the filamin B (FLNB) gene resides in this region, is the cause of skeletal dysplasias, and was identified among the top genes in our bioinformatics analysis, we hypothesized a role for FLNB in the regulation of bone structure in the general population. Using a tag single nucleotide polymorphism (SNP) approach, a family study of 767 female sibs in which the 3p14-p21 linkage with BMD was previously shown was examined. FLNB variants showing a BMD association were tested in two additional data sets, a study of 1085 UK female twins and a population study (CAIFOS) of 1315 Australian women. Genotype-expression studies were performed in 96 human osteoblast lines to examine the variants in vitro. rs7637505, rs9822918, rs2177153, and rs2001972 showed association with femoral neck (p = 0.0002-0.02) in the family-based study. The twin study provided further support for an association between rs7637505 and femoral neck and spine BMD (p = 0.02-0.03). The CAIFOS study further suggested an association between rs2177153 and rs9822918 and femoral neck BMD (p = 0.004-0.03). Prevalent fractures were increased in carriers of the A allele of rs2177153 (p = 0.009). In vitro studies showed association between rs11130605, itself in strong LD with rs7637505, and FLNB mRNA expression. These findings suggest common variants in FLNB have effects on bone structure in women. Although the location of variants having effects is not entirely consistent, variation at the 59 end of the gene may reflect effects on levels of FLNB transcription efficiency.
INTRODUCTION

P
OSTMENOPAUSAL OSTEOPOROSIS (OMIM 166710) IS a systemic bone disease characterized by disturbed microstructure of bone tissue and reduced bone mass, resulting in increased risk for fragility fracture.
(1) Peak bone mass is achieved in early adult life but declines in postmenopausal women because of a reduction in estrogen production with effects on bone and intestinal and renal calcium handling. (2) Osteoporosis diagnosis is based on the use of DXA, a noninvasive measurement of bone mass and size, and 30% of postmenopausal women meet the definition. Bone mass and size, assessed as areal BMD (aBMD), are associated with an increase in risk of fracture of 2-fold for each SD reduction in aBMD. (3) Twin and family studies show that 50-90% of the variance in peak aBMD is heritable. (4) After menopause, despite increased effects of environmental factors, BMD remains strongly genetically determined, (5) and 27-68% of the variance in osteoporotic fracture is heritable. (6) Genome-wide single nucleotide polymorphism (SNP) association scans have identified a small number of loci of genome-wide significance-but these common variants thus far explain only a fraction of the genetic variance. (7) (8) (9) Previous whole genome linkage scanning identified a number of regions and potential positional candidates for both osteopenia and osteoporosis, (4, (10) (11) (12) (13) (14) some of which (e.g., LRP5 (15) ) have been recently validated. Among these, the 3p14-p21 region (62-91 cM) has been recognized as containing a quantitative trait locus (QTL) for bone structure in a number of studies. (10, 14, 16, 17) Based on data from our replicated genetic linkage studies in families and twins, (10) extensive bioinformatics characterization of the 3p14-p21 region was undertaken that highlighted the FLNB gene as a strong functional and positional candidate. Previous data showed that mutations in the FLNB gene result in four rare human skeletal disorders, type I and III atelosteogenesis (AOI, OMIM 108720; AOIII, OMIM 108721), autosomal recessive spondylocarpotarsal syndrome (SCT, OMIM 272460), and autosomal dominant Larsen syndrome (OMIM 150250), (18, 19) thus identifying the FLNB gene and its product as playing an important role in the development of human bone disease. Further evidence of the prominence of the gene in relation to bone structure comes from targeted disruption of Flnb in the mouse in which major changes in bone size and mass occur, (20) potentially mediated by RHOA, (20) which has a role as a commitment switch in the progression of mesenchymal stem cells to osteogenic cells. (21) This paper reports a study of the effects of polymorphisms within the FLNB gene on BMD in women and on gene expression from in vitro studies.
MATERIALS AND METHODS
Subjects
Discovery study: A total of 767 women of Western European ancestry from 334 families were recruited in Australia and the United Kingdom (Table 1 ). This population was a family-based cohort and included siblings recruited for a study of the genetics of osteoporosis in 1998. (10) Exclusion criteria included the presence of bone cancer, hyperparathyroidism, unstable thyroid disease, long-term steroid use (>5 mg/d for >6 mo and presently on therapy), chronic immobility, rheumatoid arthritis, anorexia nervosa, osteomalacia, amenorrhea for >6 mo, premature cessation of regular menstruation or surgical oophorectomy with or without hormone replacement therapy (age < 40 yr), and epilepsy with use of anticonvulsant medication for >1 yr. Sibships within the cohort included 263 families with two siblings, 49 with three siblings, 17 with four siblings, 4 with five siblings, and 1 with seven siblings. At a clinic visit, data including age, height, weight, medical, gynecological, and lifestyle data were recorded, and a blood sample was collected for extraction of DNA. Among these women, 477 had reached menopause. DXA BMD was assessed (Hologic, Bedford, MA, USA) at the lumbar spine (L 1 -L 4 ) and the hip site that includes an area specifically assessing the femoral neck region.
UK twin study: All subjects were women and of Western European ancestry, unselected for any disease or trait, 18-76 yr of age. The cohort was comprised of 1085 women from the TwinsUK cohort (www.twinsuk.ac.uk), (10, 22) a population-based sample of Britons previously shown to be representative of singleton populations and the UK population in general. Among this group, 476 were postmenopausal.
CAIFOS study: The CAIFOS study population consisted of Australian women of Western European ancestry, between 72 and 85 yr of age, recruited from the electoral roll in 1988 to allow extrapolation to the general community, as described previously. (23) Of 1499 women approached, 1315 had prevalent fracture data available and agreed to provide DNA samples. DXA data were available for 1005 women. None of the participants were on bone active agents or calcium and were excluded if known to have a bone disorder or a preexisting medical condition that suggested they were unlikely to survive a 5-yr period. Collection of lumbar spine BMD phenotype data was not undertaken because of the confounding effects of degenerative joint disease in this age group. Prevalent fracture data for this cohort were obtained using a fracture history from each subject including age at time of fracture, the site, and how the fracture was sustained. A prevalent fracture was included if it occurred after the age of 50 yr and was caused by minimal trauma, as defined by falling from a height of <1 m and included wrist (43%), lower leg (17%), ribs (12%), humerus (9%), foot (9%), hand (4%), vertebrae (3%), clavicle (2%), and femur fractures (1%). Fractures of the face, skull, fingers, and toes were not included.
SNP analysis
Genotyping in the discovery and replication cohort was performed using Bead Array Assay technology (Illumina, San Diego, CA, USA), performed using protocols provided by the manufacturer and described previously. (24) Identities of the tag SNPs studied (selected using the Perlegen Genome Browser, Version 1) and experimental details are detailed in Table 2 . SNPs were selected if they tagged a linkage disequilibrium (LD) bin with tagging strength r 2 > 0.8, containing more than two variants. Two additional coding SNPs genotyped were selected from dbSNP, and one SNP, rs4681772, not represented by the selected tag SNPs, was added to fill-in a region where data on LD was thought to be sparse. x 2 testing was used to confirm that the SNPs were in Hardy-Weinberg equilibrium. The estimated genotype error rate was <0.1%. Where data for SNPs were not available from genotyping, IMPUTE software (25) was used to infer and assign genotypes. Genotyping of genomic DNA from the Australian population cohort for rs2177153 was performed using matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry (Applied Biosystems, Foster City, CA, USA) as previously reported. (26) Genotyping of all other SNPs in this cohort was performed using MALDI-ToF mass spectrometry (Sequenom, San Diego, CA USA). For this technique, the genotype error rate was <0.1%.
Gene expression analysis
Human trabecular bone from the proximal femoral shaft was collected from 96 donors undergoing total hip replacement. The bone samples from each donor were thoroughly minced and washed with PBS to remove hematopoietic cells. The bone explants were placed in three culture dishes (representing biological replicates) and osteoblast-like cells (most likely bone-lining cells, osteocytes, pre-osteoblasts, and mature osteoblasts) migrated off the bone onto the culture dish surface. The cells were grown in medium containing aMEM (Sigma-Aldrich, Suffolk, UK) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (National Veterinary Institute of Sweden, Uppsala, Sweden), and 10% FBS (Sigma-Aldrich) at 378C with 5% CO 2 until confluence. At 70-80% confluence, the cells were harvested and stored in 2708C until RNA and DNA extraction. RNA and DNA were extracted from the cell lysates using the RNeasy Mini Kit (Qiagen) and the GenElute DNA Miniprep Kit (Sigma-Aldrich), respectively. High RNA quality was confirmed for all samples using the Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA), and the concentrations were determined using a Nanodrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). Expression profiling was performed using 200 ng of total RNA and HumRef-8 BeadChips (Illumina), processed according to the protocol supplied by the manufacturer. The raw data were imported to Bioconductor using the R 2.5.0 package for variance-stabilizing transformation (VST) and robust spline normalization to obtain normalized mean expression values. Genotyping for genotypeexpression association was performed using Illumina HumanHap550-Duo BeadChip with all SNPs located in a ±250-kb window flanking the gene tested. Individuals with low genotyping rate and SNPs showing significant deviation from Hardy-Weinberg equilibrium (p < 0.05) were excluded. Similarly, low-frequency SNPs and SNPs with high rates of missing data were excluded.
Ethics approval
All subjects from the three cohorts and those who participated in the gene expression analyses provided written informed consent, and the institutional ethics committees of participating institutions approved the experimental protocols. 
Statistical analysis
Statistical analyses of clinical data were performed using STATISTICA (Ver 8.0; StatSoft, Tulsa, OK, USA). Based on data from our replicated genetic linkage studies in twins and families, we performed extensive bioinformatics characterization of the 3p14-p21 region using GeneSniffer Software (www.GeneSniffer.org). This analysis integrated data from NCBI's Gene, OMIM, and PubMed databases, established homologs of each gene by BLAST, identified mouse orthologs, and scored and weighted these data according to the degree of homology, ultimately producing a cumulative hit-score for each gene. LD (D9 and r 2 ) between different polymorphisms was evaluated using JLIN. (27) Analysis of data for the Discovery study used FBAT (Family-Based Association Tests) to test for association within families, a method based on the allelic transmission disequilibrium test. (28) The empirical variance estimator was used to allow for prior linkage to the region. We used BMD Z-scores, which define the number of SDs above or below mean of an age-matched control population, to provide a correction of BMD for age, which is necessary in the analysis of within-family effects in the discovery cohort. For consistency, BMD Z-scores were used in the analysis of all the cohorts studied. In further analyses, we accounted for potential effects of covariates by including height, weight, and menopause status in a tests of association with spine and femoral neck BMD Z-score. Significant (p < 0.05) terms were included as covariates in multiple linear regression and the standardized residual values used in subsequent analyses. Total population analysis of association data for the Discovery study and the UK twin replication study used PLINK-QFAM Total-a linear regression technique that used an additive genetic model and accounted for the relatedness of individuals in the study population. (29) Adjustment for multiple testing was done by permuting the phenotypes within sibships, with genotypes held constant. The minimum p values were recorded for 10,000 random reassignments of the data (using an automated script written in Perl), with an adjusted p 0.05 considered significant. The contribution of each allele to the mean in the family-based analysis was assessed using QPDTPHASE. (30) Haplotype imputation and testing were performed using UNPHASED. (30) Because the individuals in the Australian population study were unrelated, association between genotypes and phenotypes were examined using ANOVA with posthoc Tukey HSD test. Genotype effects on prevalent fracture rates were examined using a Pearson x 2 test. Tests of association of gene expression with SNPs were performed using a linear regression model in PLINK. (29) 
RESULTS
The demographic data for the three cohorts are shown in Table 1 .
Discovery study
The locations of the 13 tag SNPs selected from previous data to represent the major variation in FLNB sequence are shown in Table 2 . The LD observed between the tag SNPs in the Discovery study is shown in Fig. 1 . The hypothesis that FLNB gene variation regulates bone structure was first tested by assessing association with ageadjusted femoral neck and spine DXA BMD Z-score data using FBAT within-family additive genetic association models (Table 3) . These analyses showed significant associations between four tag SNPs and femoral neck BMD Z-score, among which rs2177153 showed maximal association, and this remained highly significant after adjustment for multiple testing and the observed linkage (p = 0.003). None of the SNPs showed association with spine DXA Zscore in this analysis. Next, PLINK-QFAM software was used to evaluate the total association in an additive genetic model (Table 3 ; femoral neck BMD Z-score, p = 0.007; spine BMD Z-score, p = 0.053 for rs2177153). Three main regions of association were observed, one upstream of the FLNB transcription start site (NM_001457.2 Chr 3: 57943433 bp; rs7637505), a second larger region extending from intron 1 to intron 11 (Chr 3: 58032724bp; rs9822918, Chr 3:58067386bp; rs2177153), and a third region within intron 28 (Chr 3: 58098289bp; rs2001972). The association between FLNB SNPs and femoral neck BMD Z-score remained after adjustment for covariates in the within-family test. For weight-adjusted femoral neck BMD Z-score, p values were p = 0.147, p = 0.012, p = 0.004, and p = 0.026 for rs7637505, rs9822918, rs2177153, and rs2001972, respectively. No association was evident in data for the within-family analysis of weight-and height-adjusted spine BMD Z-score (p = 0.483-0.969). For the test of total association, no site showed association after adjustment for covariates (p = 0.115-1.0), which may be because of the statistical cost of fitting the additional covariates. The correlation between the BMD Z-scores obtained for the spine and hip sites was r = 0.52.
UK twin study
A total of 1085 white dizygous female twins whose demographic details are shown in Table 1 were studied for replication of association between rs7637505, rs9822918, rs2177153, rs2001972, and DXA BMD Z-score using PLINK-QFAM for total population association (Table 4) . rs7637505 located 59 of the transcription start site showed association with femoral neck and lumbar spine BMD Z-score (p = 0.032 and p = 0.025, respectively). Analysis of weight-adjusted BMD Z-score at the femoral neck site and weight-and height-adjusted BMD Z-score at the lumbar spine site slightly improved the significance level for the association between BMD Z-score and rs7637505 (p = 0.008 and p = 0.019, respectively). No association with the other three SNPs was evident for BMD Z-score (p = 0.378-1.0) or covariate-adjusted BMD Z-score (p = 0.228-1.0).
CAIFOS study
The tag SNPs rs7637505, rs9822918, rs2177153, and rs2001972 that showed association with DXA BMD in the Discovery study were genotyped in the Australian population-based study whose demographic details are shown in Table 1 . Association with femoral neck BMD was tested in ANOVA (Table 5) 
Haplotype analysis
Using imputed haplotypes, a three-marker haplotype analysis (rs7637505, rs2177153, and rs2001972) in the Discovery study showed that >97% of the population can be represented by five haplotypes: A-A-C (51%), T-G-A (17%), A-G-A (13%), T-A-C (10%), and A-A-A (6%). Significant associations between the haplotypes and femoral neck BMD Z-score were observed based on QPDTPHASE analysis (p = 0.008). The A-A-C haplotype showed the lowest femoral neck BMD Z-score among common haplotypes (BMD Z-score = 20.418 ± 1.046; mean ± SD, p = 0.012 versus all other haplotypes). The presence of the T-G-A haplotype was associated with an elevated femoral neck BMD Z-score (mean BMD Z-score = 20.262 ± 1.046, p = 0.006 versus all other haplotypes). However, haplotype analysis did not result in improved significance level for the other two studies compared with the analysis of individual SNPs.
In vitro studies
To further characterize the role of sequence variation in cis-regulation of FLNB gene expression, profiling of FLNB mRNA in cultured human osteoblast cells derived from 96 unrelated donors was undertaken (Table 6 ). Three of the variants, associated with femoral neck BMD in the population studies (rs9822918, rs2177153, and rs2001972) were not associated with FLNB mRNA expression levels. rs7637505 was not studied directly because it was not represented on the analysis chip. However, significant association was observed for SNPs in the 59end of FLNB, which were in strong LD with the SNPs associated with DXA BMD in the population studies, in particular, rs7637505 and rs2177153. The SNP rs11130605, located 5 kb upstream of the transcription start site of the gene, showed strong association with FLNB RNA expression. Also of note is the high level of LD (D9 = 0.72) between rs9809315, showing a genotype-expression association (p = 0.002; Table 6 ), and rs2177153, showing a strong genotype-phenotype association.
DISCUSSION
These data show that polymorphic sequence variants in the FLNB gene have effects on bone structure in women. Data from the Discovery study supports our original hypothesis that femoral neck BMD is associated with four SNPs in three possible gene regions, and there is limited evidence of association with an additional SNP, 59 of the transcription start site, from genotype-expression studies. Data from the Australian study supports an association of rs9822918 and rs2177153 with femoral neck BMD and for the latter of these with fracture. Data from the twins study is less supportive. These are tag SNPs and would not necessarily be expected to be the functional variants; however, rs11130605 and rs9809315, in relatively strong LD with rs7637505 and rs2177153, respectively, do show significant association with the level of gene transcription in vitro and are potentially related to transcriptional control elements (e.g., such as that seen for SHH (31) ; OMIM 600725). Therefore, they may represent the quantitative trait nucleotides (QTNs), but the underlying LD is complex. We performed only a sampling of SNPs in this gene. We did this in an attempt to gain insight and to aid in prioritization of specific regions of the gene for further study. This approach has yielded three potentially relevant regions showing associations and provides a solid foundation on which to plan further detailed studies.
Overall, these data provide evidence that common DNA sequence variants are associated with femoral neck bone structure in women in the general population. In addition, data showing an association with spine BMD in the twin study, combined with data on fragility fracture (at various sites) in the CAIFOS study, suggests the possibility of a pleiotropic effect of variation in FLNB on the regulation of bone structure at multiple anatomical locations. Although it has been shown that gross aberration in function of Filamin B caused by missense mutation and frameshift deletion results in serious alterations to bone formation and microarchitecture and is the basis for several osteochondrodysplasia syndromes, (18, 19) this is the first report of common polymorphisms in this gene being involved in the regulation of bone structure in the general population. Our data from the population replication sample suggests that the effect size on BMD attributable to FLNB polymorphisms is of the order of 4% and comparable to the effect size of other bone structure-related genes such as LRP5 (15, 32) and BMP2. (33) The variants examined for FLNB are common; for example, >45% of the UK and Australian individuals in the replication studies (Tables 4  and 5 ) were homozygous for the low BMD allele of rs2177153.
The protein product of the FLNB gene is a 280-kDa actin binding protein (FLNB), which is capable of crosslinking actin in the cytoskeleton to provide the scaffolding system on which intracellular signaling and protein trafficking can occur. (34) FLNB is very similar to FLNA, and the genes encoding these proteins share ;70% amino acid sequence homology. Mutations in the FLNA gene are also known to cause a skeletal phenotype (otopalatodigital spectrum disorders; OMIM 304120, OMIM 311300); however, data from association studies examining tSNP in FLNA have shown no evidence of association with aBMD in the general population.
The severe phenotype and poor viability of the Flnb 2/2 mouse suggests that the pathway is nonredundant. (20) That model also provides evidence that some of the effects of the FLNB protein may be mediated through RHOA. (20) A role for RHOA has been reported in the progression of mesenchymal stem cells to osteogenic cells, thus regulating bone formation. Other studies suggest a possible role of RHOA in bone resorption. (35) Thus, elevated levels of FLNB may induce a reduction in RHOA expression, with concomitant reductions in osteoblast differentiation and bone formation. RHOA is specifically activated by the protein product of the ARHGEF3 gene, (36) and we have previously shown significant associations between sequence variation in that gene and BMD in white women, (37) potentially suggesting the relevance of genetic variation in regulation of multiple genes in the pathway.
Finally, a recent genome-wide association (GWA) study of stature by Lei et al. (38) showed association between eight SNPs in two haplotype blocks of FLNB and age-and sexadjusted body height. Those data compliment previous reports showing that mutations in the FLNB gene are commonly associated with alterations in stature (18) and animal data from the Flnb null mouse showing effects on shortened bone lengths, reduced weight, and lower BMD (20) and reiterates the pleiotropic effects of filamin B. In conclusion, gene variation in FLNB is a determinant of hip structure in white women. Although rs11130605 may be a QTN, further study by direct genotyping of this and other variants showing association with expression levels is needed to confirm if this is the only QTN. Additional research is also needed to elucidate the precise molecular mechanism of the observed regulatory effect for this variant. These data on FLNB variants together with other recently identified gene variants (8, 9) may be of value in early diagnosis of women who are at risk for developing osteoporosis and may lead to identification of novel therapeutic pathways. FLNB REGULATES BMD 1995
